Twist Bioscience Corp (TWST)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NASDAQ
Market Cap: $7.40B
Last updated: Nov 17, 2026 at 11:06 AM ET
Twist Bioscience Corp (TWST) Stock Forecast
Analysts expect Twist Bioscience (TWST) to earn -$0.40 per share in the fiscal year ending Sep 30, 2027, on revenue of $548.67M. Of 13 analysts, 9 rate the stock Buy or Strong Buy, 3 Hold and 1 Sell or Strong Sell, for a consensus of Buy. Over the last 30 days, 1 estimate for the fiscal year ending Sep 30, 2027 was revised up and 0 down.
Analyst Ratings
Scoring Strong Buy as 1 and Strong Sell as 5, the 13 ratings average 2.23, inside the Buy band from 1.5 up to 2.5. Buy and Strong Buy make up 69% of the ratings.
| Rating | Analysts | Share |
|---|---|---|
| Strong Buy | 2 | 15.4% |
| Buy | 7 | 53.8% |
| Hold | 3 | 23.1% |
| Sell | 1 | 7.7% |
| Strong Sell | 0 | 0.0% |
- Consensus
- Buy
- Total analysts
- 13
Price Target
Analyst price targets are part of paid GNG plans. See plans
Annual Estimates
From the first fiscal year below to the second, the EPS consensus turns from a loss to a profit and revenue estimates rise 17.7%.
- Fiscal year ending Sep 30, 2027
- -$0.40
- EPS consensus, revenue $548.67M
- Fiscal year ending Sep 30, 2028
- $0.98
- EPS consensus, revenue $645.83M
- Next report
- Feb 1, 2027
- Estimated
EPS range
Revenue range
| Fiscal year ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Sep 30, 2027 | -$0.40 | -$1.12 to $0.10 | 4 | $548.67M | $532.40M to $559.88M | 11 |
| Sep 30, 2028 | $0.98 | $0.90 to $1.05 | 2 | $645.83M | $628.36M to $662.30M | 9 |
Quarterly Estimates
The EPS consensus rises from -$0.14 for the quarter ending Dec 31, 2026 to -$0.11 for the quarter ending Mar 31, 2027.
EPS range
Revenue range
| Quarter ending | EPS consensus | EPS range | EPS analysts | Revenue consensus | Revenue range | Rev. analysts |
|---|---|---|---|---|---|---|
| Dec 31, 2026 | -$0.14 | -$0.31 to -$0.04 | 3 | $126.42M | $124.00M to $128.13M | 8 |
| Mar 31, 2027 | -$0.11 | -$0.30 to $0.00 | 3 | $133.21M | $130.10M to $136.32M | 8 |
Estimate Revisions
Across the 4 periods below, the last 30 days brought 2 upward and 2 downward EPS revisions.
| Period | Up 30 days | Down 30 days |
|---|---|---|
| Fiscal year ending Sep 30, 2027 | 1 | 0 |
| Fiscal year ending Sep 30, 2028 | 0 | 1 |
| Quarter ending Dec 31, 2026 | 1 | 0 |
| Quarter ending Mar 31, 2027 | 0 | 1 |
EPS Trend
Over the last 90 days, the EPS consensus for the fiscal year ending Sep 30, 2027 has improved from -$1.00.
| Period | Now | 7 days ago | 30 days ago | 60 days ago | 90 days ago | Change |
|---|---|---|---|---|---|---|
| Fiscal year ending Sep 30, 2027 | -$0.40 | -$0.75 | -$0.75 | -$0.78 | -$1.00 | N/A |
| Fiscal year ending Sep 30, 2028 | $0.98 | $0.12 | $0.12 | $0.12 | -$0.03 | N/A |
| Quarter ending Dec 31, 2026 | -$0.14 | -$0.16 | -$0.16 | -$0.16 | -$0.10 | N/A |
| Quarter ending Mar 31, 2027 | -$0.11 | -$0.10 | -$0.10 | -$0.10 | -$0.06 | N/A |
Frequently Asked Questions About TWST
What is the TWST stock forecast?
Consensus analyst estimates put Twist Bioscience's EPS at -$0.40 for the fiscal year ending Sep 30, 2027, on revenue of $548.67M. The consensus rating from 13 analysts is Buy.
How do analysts rate TWST stock?
Of 13 analysts covering Twist Bioscience, 2 rate it Strong Buy, 7 Buy, 3 Hold, 1 Sell and 0 Strong Sell, for a consensus of Buy.
What EPS do analysts expect from TWST next year?
For the fiscal year ending Sep 30, 2027, the consensus EPS estimate is -$0.40, with estimates from -$1.12 to $0.10 from 4 analysts. For the fiscal year ending Sep 30, 2028, the consensus EPS estimate is $0.98, with estimates from $0.90 to $1.05 from 2 analysts.
What revenue do analysts expect from Twist Bioscience next year?
For the fiscal year ending Sep 30, 2027, the consensus revenue estimate is $548.67M, with estimates from $532.40M to $559.88M. For the fiscal year ending Sep 30, 2028, the consensus revenue estimate is $645.83M, with estimates from $628.36M to $662.30M.
How many analysts cover TWST?
13 analysts rate Twist Bioscience stock, and 4 analysts estimate its EPS for the fiscal year ending Sep 30, 2027.
TWST pages: Overview, Earnings, Forecast, Financials, Competitors, Government Contracts